Предыдущая страница реферата | 1  2  3  4  5  6  7  8 | Следующая страница реферата

Kotsa K., Watson P.F., Weetman A.P. A CTLA-4 gene polymorphism is associated with both Graves' disease and Hashimoto's thyroiditis. // Clin Endocrinol — 1997 — Vol. 46. — P. 551 — 555.

Tomer Y., Barbesino G., Greenberg D.A., Concepcion E., Davies T.F. Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: Evidence for genetic heterogeneity and gene interactions. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 4656 — 4664.

Imrie H., Vaidya B., Perros P., et al. Evidence for a Graves' disease susceptibility locus at chromosome Xp11 in a United Kingdom population. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 626 — 630.

Chiovato L., Pinchera A. Stressful life events and Graves' disease. // Eur J Endocrinol. — 1996 — Vol. 134. — P. 680 — 682.

Coles A., Wing M., Smith S., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. // Lancet — 1999 — Vol. 354 — P. 1691-1695.

Sato A., Takemura Y., Yamada T., et al. A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 3602 — 3605.

Rapoport B., Chazenbalk D., Jaume J.C., McLachlan S.M. The thyrotropin (TSH) receptor: Interaction with TSH and autoantibodies. // Endocrine Rev — 1998 — Vol. 19. — P. 673 — 716.

Pichurin P., Pichurina O., Chazenbalk G.D., et al. Immune deviation away from Th1 in interferon-г knockout mice does not enhance TSH receptor antibody production after naked DNA vaccination. // Endocrinology — 2002 — Vol. 143. — P. 1182-1189.

Chazenbalk G.D., McLachlan S.M., Pichurin P., Yan X-M., Rapoport B. A prion-like shift between two conformational forms of a recombinant thyrotropin receptor receptor A-subunit module: Purification and stabilization using chemical chaperones of the form reactive with Graves' autoantibodies. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 1287 — 1293.

Metcalfe R., Jordan N., Watson P., et al. Demonstration of immunoglobulin G, A, and E autoantibodies to the human thyrotropin receptor using flow cytometry. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 1754-1761.

McIntosh R.S., Tandon N., Pickerill A.P., Davies R., Barnett D., Weetman A.P. IL-2 receptor-positive intrathyroidal lymphocytes in Graves' disease. Analysis of Vб transcript microheterogeneity. // J Immunol — 1993 — Vol. 151. — P. 3884-3893.

Soliman M., Kaplan E., Yanagawa T., Hidaka Y., Fisfalen M-E., DeGroot L.J. T cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain. // J Clin Endocrinol Metab — 1995 — Vol. 80. — P. 905-914.

Ajjan R.A., Kemp E.H., Waterman E.A., et al. Detection of binding and blocking autoantibodies to the human sodium-iodide symporter in patients with autoimmune thyroid disease. // J Clin Endocrinol Metab — 2000 — Vol. 85. — P. 2020-2027.

Metcalfe R.A., McIntosh R.S., Marelli-Berg F., Lombardi G., Lechler R., Weetman A.P. Detection of CD40 on human thyroid follicular cells: Analysis of expression and function. // J Clin Endocrinol Metab — 1998 — Vol. 83. — P. 1268 — 1274.

Schwartz K.M., Fatourechi V., Ahmed D.D.F., Pond G.R. Dermopathy of Graves' disease (pretibial myxedema): Long-term outcome. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 438-446.

Davies T.F., Roti E., Braverman L.E., DeGroot L.J. Controversy-Thyroid stimulating antibodies. // J Clin Endocrinol Metab — 1998 — Vol. 83. — P. 3777-3785.

Costagliola S., Morgenthaler N.G., Hoermann R., et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 90-97.

Meller J., Jauho A., Hufner M., Gratz S., Becker W. Disseminated thyroid autonomy of Graves' disease: Reevaluation by a second generation TSH-receptor-antibody assay. // Thyroid — 2000 — Vol. 10. — P. 1085-1091.

Feldt-Rasmussen U., Schleusener H., Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on longterm remission after medical therapy of Graves' disease. // J Clin Endocrinol Metab — 1994 — Vol. 78. — P. 98-102.

Ljunggren J-G., Torring O., Wallin G., et al. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: Results from a prospective, randomized study. // Thyroid — 1998 — Vol. 8. — P. 653-659.

Duh Q-Y. Thyroidectomy for the treatment of Graves' disease. // Thyroid — 1999 — Vol. 9. — P. 259-261.

Singer P.A., Cooper D.S., Levy E.G., et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. // JAMA — 1995 — Vol. 273. — P. 808 — 812.

Vanderpump M., Ahlquist J., Franklyn J.A., Clayton R.N. on behalf of a working group of the Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. // BMJ — 1996 — Vol. 313. — P. 539-544.

Allahabadia A., Daykin J., Holder R.L., Sheppard M.C., Gough S., Franklyn J.A. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. // J Clin Endocrinol Metab — 2000 — Vol. 85. — P. 1038-1042.

Weetman A.P., Pickerill A.P., Watson P., Chatterjee V.K., Edwards O.M. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs. The effect of treatment duration and immunogenetic susceptibility on relapse. // QJM — 1994 — Vol. 87. — P. 337 — 341.

Рекомендуем скачать другие рефераты по теме: шпаргалки для студентов, титульный дипломной работы.





Предыдущая страница реферата | 1  2  3  4  5  6  7  8 | Следующая страница реферата